Brief: Sino Biopharmaceutical Says TRD221 Receives NMPA Clinical Trial Approval For Osteoarthritis Treatment
17/03/2026 10:13
March 17 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK: TRD221 RECEIVES NMPA CLINICAL TRIAL APPROVAL FOR OSTEOARTHRITIS TREATMENT Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit